MetalDrug encodes therapeutic intent as deterministic physical constraints — not statistical guesses. Every blueprint is ZK-verified, Merkle-anchored, and traceable to first principles of coordination chemistry.
Validating the Collapse of Regulatory Timelines
The FDA accepted the SEI-generated in silico data as definitive bridging evidence under the FDA Modernization Act 2.0. Zero novel animal data was submitted. This validates the core Moleculogic axiom: deterministic computational logic can successfully and legally replace empirical trial-and-error bottlenecks.
The difference is not speed. It is epistemic architecture. One system produces approximations. The other produces proofs.
MDC, FDC, and Moleculogic are layered reasoning systems operating on the same SEI constraint kernel.
Coordination chemistry encoded as constraint tensors. Ruthenium, zinc, and platinum-core therapeutics designed from first-principle ligand field theory.
Multi-agent therapeutic combinations governed by biochemical interaction tensors. Synergy surfaces computed, not assumed. QRX-3 validated this architecture against the FDA.
AskMo, blueprint generation, entropy scoring, ZK-anchoring, and ExergyNet compute dispatch — unified under the SEI deterministic inference standard.
Every MetalDrug simulation routes through ExergyNet — a ZK-verified decentralized compute network. The proof is on-chain. The data is yours.
Every blueprint simulation dispatched to the ExergyNet prover swarm. RISC Zero zkVM generates a ZK-STARK receipt. Settled in USDC on Base L2. The computation is mathematically proven — not claimed.
Every blueprint is SHA-256 hashed, Merkle-chained, and anchored to the LNES-04 Base L2 ledger via your Ed25519 signing key. The timestamp is permanent. The chain is unbreakable.
Legacy cloud providers extract corporate margins on top of hardware and energy costs. ExergyNet routes work to prover nodes competing on electricity price alone.
Each asset has passed SEI entropy scoring and ZK-verified simulation gates.
| Asset | Indication | Mechanism | Stage | Readiness |
|---|---|---|---|---|
QRX-3 FDC-CKD · NCT06866236 |
Chronic Kidney Disease | Redox buffering · Mito stabilization | Phase 2/3 · Active | |
MDC-Ru-216 FDC-SARCO-01 |
Sarcomatoid Carcinoma | ROS amplification · Platinum synergy | Tier 3 · Pre-clinical | |
GRX-REGEN-χ1 FDC-REGEN-GRX |
Dermatology / Hair Loss | MITF upregulation · Stem cell regeneration | Tier 2 · Mechanism Val. |
All pipeline candidates are simulation-validated. No candidates have received IND approval or entered FDA-registered clinical trials except QRX-3 (NCT06866236) as of this date.
Tiered access reflects increasing institutional verification, not arbitrary paywalls.